Myriad Genetics, Inc. MYGN
Myriad Genetics, Inc. (Nasdaq: MYGN) is a diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Nov 4, 2026submitted Myriad submitted a request to National Government Services, a Medicare Administrative Contractor, for a Local Coverage Determination to establish Medicare coverage of Precise MRD test for breast cancer patients.
GBA, a Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services, for a Local Coverage Determination to establish Medicare coverage of its Precise MRD test for breast cancer patients.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.